RecruitingACTRN12611000012976

Microencapsulation for Enhanced Bioavailability of Fish Oil - Acute Study

Microencapsulation for Enhanced Bioavailability of Fish Oil in Healthy Adult Volunteers - Acute Study


Sponsor

CSIRO Preventative Health Flagship

Enrollment

15 participants

Start Date

Oct 18, 2010

Study Type

Interventional

Conditions


Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 70 Yearss

Plain Language Summary

Simplified for easier understanding

Omega-3 fatty acids (found in fish oil) are known to be good for your heart and overall health, but your body may not absorb them very well from standard supplements. This study is testing a new way of packaging fish oil — called microencapsulation — to see if it helps your body absorb the omega-3s more effectively. Participants take different forms of the fish oil supplement and then researchers measure how much omega-3 gets into the bloodstream over the following hours. You may be eligible if: - You are a male or female between 18 and 70 years old - You eat a normal diet (no medically prescribed, strict weight-loss, vegan, or macrobiotic diet) - Your body mass index (BMI) is between 18 and 35 kg/m² - You are generally healthy with no significant metabolic, digestive, kidney, or heart disease You may NOT be eligible if: - You have taken omega-3 supplements regularly in the past 2 months - You regularly eat foods fortified with omega-3 (such as some breads or milks) - You regularly eat fish as part of your normal diet - You drink heavily (more than 21 standard drinks per week) - You have food allergies or intolerances (e.g., dairy, nuts, shellfish) - You have a history of substance abuse in the past 12 months - You have participated in another research study in the past 3 months Talk to your doctor about whether this trial might be right for you.

This is a simplified summary. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

This study will compare the short term bioavailability of 3 delivery systems containing omega-3 oils. They are (1) gel capsules versus (2) MicroMAX 1 powder – formulated with milk protein-sugar versus

This study will compare the short term bioavailability of 3 delivery systems containing omega-3 oils. They are (1) gel capsules versus (2) MicroMAX 1 powder – formulated with milk protein-sugar versus (3) MicroMAX powder - formulated with milk protein-sugar-resistant starch) when combined with a flavoured milk in individuals. Bioavailability will be assessed by measurement of EPA & DHA in blood/plasma. This is a crossover design study in which all participants will receive the three treatments with a washout period of 6 weeks between each treatment. To investigate the bioavailability of a single dose of omega-3 oils delivered via the three above mentioned formats over 48 hrs. The two different MicroMAX powders (one formulated with milk protein-sugar and other milk protein-sugar-resistant starch) will each be provided as an 8g serve containing a dose of 500mg/g omega-3 oil. The gel capsules will be given as a one-off dose of 4 capsules (each capsule will contain 1000mg of omega-3 oil).


Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12611000012976